BioLineRx draws approaches for schizophrenia pill, CFO says (Bloomberg Business Week) - May 23, 2012 - P2/3, N=435; Study ID: NCT01363349; BL-1020 improved pts' cognitive function in a mid-stage trial in 2010 & BioLineRx expects results from a more advanced study in 2013
Anticipated P2/3 data • Schizophrenia
|
|
BioLineRx Ltd. (BLRX), an Israeli drug development company partly held by Teva Pharmaceutical Industries Ltd. (TEVA) (TEVA), said it’s been approached by larger drugmakers interested in developing its experimental schizophrenia pill.
The medicine improved patients’ cognitive function in a mid-stage trial in 2010 and the company expects results from a more advanced study next year, Chief Financial Officer Philip Serlin said. Partnership talks will probably “heat up” then, according to Serlin.
BioLine, based in Jerusalem, says its BL-1020 drug may turn out to help patients function better in daily life while anti- psychotic medicines such as AstraZeneca Plc (AZN)’s Seroquel and Johnson & Johnson (JNJ) (JNJ)’s Risperdal help quell schizophrenia symptoms such as hearing voices or violent outbursts.
|